117 related articles for article (PubMed ID: 2453091)
1. Carboplatin (JM 8), adriamycin and cyclophosphamide (JAC) in advanced ovarian carcinoma: a pilot study.
Conte PF; Bruzzone M; Chiara S; Rosso R; Giaccone G; Carnino F; Guercio E; Ragni N; Foglia G; Bentivoglio G
Tumori; 1988 Apr; 74(2):217-20. PubMed ID: 2453091
[TBL] [Abstract][Full Text] [Related]
2. 300 mg/m2 carboplatin (Cb), adriamycin (A) cyclophosphamide (C) (CACb-300) combination in advanced ovarian carcinoma: a feasibility study.
Martin P; Bugat R; Pinon G; Pinel MC; Heritier F; Chazard M; Delestrain MC; Belpomme D
Cancer Chemother Pharmacol; 1989; 23(5):331-2. PubMed ID: 2468426
[TBL] [Abstract][Full Text] [Related]
3. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
4. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.
Edmonson JH; McCormack GW; Krook JE; Long HJ; Jefferies JA; Richardson RL
Cancer Treat Rep; 1987 Feb; 71(2):199-200. PubMed ID: 3542210
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study.
Eiermann W; Achterrath W; Lenaz L; Hepp H
Cancer Chemother Pharmacol; 1991; 27(5):389-93. PubMed ID: 1998999
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.
Alberts D; Mason N; Surwit E; Weiner S; Hammond N; Deppe G
Cancer Treat Rev; 1985 Sep; 12 Suppl A():83-92. PubMed ID: 3910225
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery.
Pickel H; Petru E; Lahousen M; Stettner H; Lehnert M
Oncology; 1989; 46(4):222-5. PubMed ID: 2662087
[TBL] [Abstract][Full Text] [Related]
10. Cis-platin in combination with low dose adriamycin and cyclophosphamide in advanced ovarian carcinoma.
Verheijen RH; Beex L; Wagener DJ; Kenemans P
Eur J Gynaecol Oncol; 1985; 6(2):116-20. PubMed ID: 3839751
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Andersson H; Friberg LG; Horvath G; Johansson O; Akesson M; Westberg R
Acta Oncol; 1995; 34(6):821-7. PubMed ID: 7576751
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.
Martoni A; Panetta A; Angelelli B; Melotti B; Pannuti F
J Chemother; 1993 Feb; 5(1):47-51. PubMed ID: 8459265
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
[TBL] [Abstract][Full Text] [Related]
15. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
Reyno LM; Egorin MJ; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
J Clin Oncol; 1993 Jun; 11(6):1156-64. PubMed ID: 8501502
[TBL] [Abstract][Full Text] [Related]
16. Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide.
Green JA; Smith K
Cancer Chemother Pharmacol; 1990; 26 Suppl():S22-5. PubMed ID: 2189593
[TBL] [Abstract][Full Text] [Related]
17. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer.
Smith HO; Goldberg GL; Carol L; Davidson SA; Tomaino C; Centrilla L; Runowicz CD
Eur J Gynaecol Oncol; 1994; 15(6):411-7. PubMed ID: 7875155
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the renal function in patients with ovarian carcinoma subjected to polychemotherapy including cisplatin or carboplatin].
Gadducci A; Facchini V; Dell'Arciprete T; Del Bravo B; Galigani P; Palla R; Fioretti P
Minerva Ginecol; 1988 Jan; 40(1):33-8. PubMed ID: 3287233
[No Abstract] [Full Text] [Related]
20. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
du Bois A; Lück HJ; Bauknecht T; Möbus V; Bochtler H; Diergarten K; Meerpohl HG
Ann Oncol; 1997 Apr; 8(4):355-61. PubMed ID: 9209665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
